Strides Shasun’s wholly owned subsidiary, Strides Pharma Global Pte has received final approval from the United States Food & Drug Administration (USFDA), for Ketoconazole tablets USP, 200 mg.

Ketoconazole tablets is a generic version of Nizoral tablets, 200 mg, of Janssen Pharmaceuticals, Inc and is used to treat certain serious fungal infections in the body. It works by stopping the growth of the fungus.

Furthermore, Ketoconazole tablet will be manufactured at the company’s oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week